This event will provide an overview of the state of the science and clinical practice of digital therapeutics as well as the current and anticipated multiple paths to their global deployment.

Digital therapeutics – software used to prevent, treat, or manage a medical disorder or disease – are redefining the future of healthcare. Digital therapeutics package an entire model of care – that can be delivered with fidelity and in accordance with state-of-the-science best practices – into a unified, seamless digital delivery system. Digital therapeutics have been particularly transformative in the field of substance use, mental health and other behavioral health conditions and can markedly improve access to care, quality of care, and treatment outcomes, while reducing costs, for a wide array of audiences in diverse settings.

The need for digital therapeutics has surged to an unprecedented level in recent years during the ongoing global COVID-19 pandemic, as demand for remote models of healthcare has greatly increased and the behavioral health needs of the world’s population have grown exponentially. These needs include marked increases in mental health and substance use problems due to factors including the social isolation, loss of loved ones, economic harms, stress, fatigue, and burnout associated with COVID – as well as the persistent effects of long COVID on people’s health, well-being and functioning.

At the same time, investment and activity in the realm of digital therapeutics have exploded globally in recent years. The number of technology start-ups focused on digital therapeutics has grown tremendously in just the past couple of years, and large global pharmaceutical companies are also increasingly launching digital therapeutics initiatives. And a growing array of paths for deploying clinically-validated digital therapeutics to patients has emerged. In the U.S., such paths range from prescriptions for digital therapeutics from qualified healthcare providers to activation codes for digital therapeutics supported by a payor, employer, or pharmacy benefit manager. And several other countries support national coverage frameworks for digital therapeutics. This Digital Health Summit will address timely opportunities for digital therapeutics and a vision for the future.

Event Location: Hanover Inn Dartmouth, 2 E Wheelock St, Hanover, NH 03755

Lodging: A block of rooms is being held at Hanover Inn Dartmouth for the nights of 11/1 and 11/2, under “Digital Health Summit Call-In Block.” Individuals can call to reserve: (603) 643-4300. Please note that rooms are limited, so reservations should be made as soon as possible.

8:00-8:30 am ET: Registration and Breakfast

8:30-8:45 am: Welcome (Lisa Marsch, Director, Center for Technology and Behavioral Health at Dartmouth College)

8:45-9:00 am: Opening Remarks (David Kotz, Provost, Dartmouth College)

9:00-9:45 am: Overview of Digital Therapeutics: Definition/Categories/Value (Andy Molnar, Chief Executive Officer, Digital Therapeutics Alliance)

9:45-9:50 am: Access to Prescription Digital Therapeutics Act of 2022 (Jeanne Shaheen, U.S. Senator from New Hampshire) 

9:50-10:20 am: Overview of Clinically-Validated Digital Therapeutics Research at the National Institutes of Health: Models of Development and Scientific Evaluation (Will Aklin, Director, Behavioral Therapy Development Program, Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse, National Institutes of Health)

10:20-10:45 am: Morning Break

10:45 am-12:15 pm: Diverse Paths to Deployment of Digital Therapeutics

• 10:45-11:00: U.S. Food and Drug Administration (FDA) Regulatory Process/Early Payor Feedback Program (Danielle Fau, Advisor for Technology and Innovation, FDA)
• 11:00-11:35: Pharmacy Benefit Manager path to digital health formularies (Zachary Goodman, Director, Clinical Innovation, Evernorth)
• 11:35-12:15: Perspective from a Digital Health Company (Corey McCann, President and CEO, Pear Therapeutics)

12:15-1:15 pm: Lunch

1:15-2:45 pm: Timely Opportunities with Digital Therapeutics and a Vision for the Future: A Panel Discussion
 (Panelists: Digital Therapeutics Companies, Payors and Investors)

• Ben Parcher, Global Market Access Lead, CNS Digital Therapeutics, Boehringer Ingelheim Pharmaceuticals, Inc.
• McKaye Black, Senior Business Design Strategist, Blue Cross Blue Shield C1 Innovation Lab
• Monica Martin de Bustamente, Senior Partner, Evidence, Value, Access & Pricing, Trinity Life Sciences
• Tripp Peake, Managing Partner, LRVHealth
• Co-Facilitators: Duane Compton, Dean, Geisel School of Medicine at Dartmouth College and Joanne Conroy, President and CEO, Dartmouth Health

2:45-2:55 pm: Afternoon Break

2:55-3:15 pm: Dartmouth Innovation Accelerator for Digital Health (Barry Schweitzer, Associate Director, Magnuson Center for Entrepreneurship at Dartmouth College and Lisa Marsch, Director, Center for Technology and Behavioral Health at Dartmouth College)

3:15-4:35 pm: Innovations in Digital Health Research at the Center for Technology and Behavioral Health at Dartmouth College

• 3:15-3:35: Enhancing the Assessment and Treatment of Mental Health using Technology and Passively Collected Data (Nicholas Jacobson, Assistant Professor of Biomedical Data Science and Psychiatry, Geisel School of Medicine, Dartmouth College)
• 3:35-3:55: Designing Interactive Health Technologies that Promote Equitable and Inclusive Care Through a "Qualified Us" Approach: A Case Study in Music-Based Interventions (Elizabeth Murnane, Charles H. Gaut and Charles A. Norberg Assistant Professor, Thayer School of Engineering, Dartmouth College)
• 3:55-4:15: Moonshot for Mental Health (Andrew Campbell, Albert Bradley 1915 Third Century Professor, Computer Science, Dartmouth College)
• 4:15-4:35: Scaling up Science-Based Behavioral Health Care at a National Level via Digital Health:  A Demonstration Project in Latin America (Lisa Marsch, Director, Center for Technology and Behavioral Health at Dartmouth College)

4:35-4:45 pm: Concluding Comments (Lisa Marsch, Director, Center for Technology and Behavioral Health at Dartmouth College)

4:45-6:00 pm: Reception